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SUMMARY
The disturbance in thiol expression characteristic of 
RA was investigated to determine whether it plays a role in 
the pathogenesis of the disease. This was studied by 
culturing mononuclear cells in a mitogen-driven system in 
v i t r o . Blockage of serum SH groups did not appear to 
influence mitogenic proliferation of mononuclear cells in 
vitro. However, mononuclear cell surface SH groups appear to 
be very much involved in both proliferation and immunoglobulin 
production. Both cell proliferation and antibody production 
can be abrogated by blocking the cell surface SH groups. It 
was shown that rheumatoid mononuclear cells produce less IgG 
than normal cells when stimulated with pokeweed mitogen in 
vitro. It was also shown that rheumatoid mononuclear cells 
will, however, make normal amounts of IgG following the 
addition, in vitro, of a simple thiol 2-mercaptoethanol (2- 
ME). Normal IgG synthesis was also observed by mononuclear 
cells from patients treated with D-penioillamine. The 
investigation showed that rheumatoid monocytes are defective 
accessory cells in the IgG production assay and that their 
function is corrected by 2-ME. However, both monocytes and 
lymphocytes must be incubated with 2-ME for normal IgG 
synthesis to occur. We have therefore demonstrated a membrane 
SH dependent interaction between monocytes and lymphocytes 
that is necessary for the production of IgG. The interaction 
does not appear to involve soluble mediators such as the
interleukins or antigen presentation but rather the physical 
interaction between the lymphocytes and monocytes. This 
interaction is defective in RA and may be involved in the 






Rheumatoid arthritis (RA) is a disease of unknown 
aetiopathogenesis in which control of inflammatory and 
immunological processes appears to be aberrant, and which is 
probably multifactorial in origin (Panayi, et al., 1981). RA 
is chiefly characterised by an erosive i n f l ammatory  
polyarthropathy, which classically begins in the small joints 
of the hands and feet and progresses symmetrically in a 
centripetal fashion. Any or all of the body's 187 synovial 
joints may be affected, each presenting different clinical 
problems due to functional disturbances (Fye et al., 1978; 
Barnes, 1980).
1.2 STRUCTURE OF THE SYNOVIAL JOINT
Joints that permit free movements are enclosed in a 
fibrous capsule. The capsule is lined by a serous synovial 
membrane which also covers the end of each bone, except where 
it is replaced by articular cartilage. It secretes the 
synovial fluid which fills the synovial cavity. The synovial 
fluid acts as a lubricant, permitting free movement of the 
parts upon one another. The bones of the joint are held in
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close alignment by tough connective tissue ligaments (Fig. 1). 
The synovial membrane consists of two layers - an intimai 
layer next to the joint cavity and a layer of connective 
tissue and fat upon which it lies. The intima is 
predominantly cellular with an abundant blood supply, whereas 
the subsynovial layer is more fibrous and less vascular 
(Barnett et al., 1961).
The functions of the cells of the synovial membrane are 
the production of synovial fluid and the removal of synovial 
fluid and detritus from the joint space. The joint fluid is 
essentially a transudate from the blood to which is added 
hyaluronic acid. Type A cells are active in phagocytosis and 
secretion. Type B cells are thought to synthesise the 
hyaluronic acid. In addition there is an intermediate or type 
AB cell which combines the features of both A and B cells and 
Ghadially, (1983) has suggested that A and B cells are not 
different cell types, but variants whose morphology is 
dependent upon functional activity.
1.3 PATHOLOGY OF THE RHEUMATOID JOINT
In RA the synovial membrane becomes thickened and in the 
active phases of this disease, exhibits exuberant villus 
formation. As inflammation proceeds tongues of inflamed villi 
become adherent to the adjacent margins of the articular 
cartilage, breaking down the cartilage as it spreads slowly
- 3 -
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Fig.l Diagrammatical cross-section showing
the structure of the typical synovial joint.
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over it. The tissue, known as pannus, is essentially a sheet 
of fibro-vascular granulation tissue arising from the 
perichondral synovial membrane (Barnes, 1980). It is the 
pannus which is believed to be the source of degradative 
enzymes which destroy cartilage and bone (Harris, 1976). The 
articular cartilage becomes increasingly overgrown by pannus 
which subsequently becomes transformed into relatively 
acellular mature fibrous tissue, and the resulting fibrous 
ankylosis leads to increasingly restricted movements in the 
affected joints (Barnes, 1980).
Articular cartilage is composed of a small number of 
chondrocytes embedded in a matrix of collagen fibrils 
entrapped in a ground substance rich in water and 
proteoglycans. It is the osmotic pressure of the water taken 
up by the proteoglycans retained and restrained by the 
collagen network which gives cartilage its resilience and its 
load bearing properties, (Ghadially, 1983). Shortly after the 
onset of synovitis, the rheumatoid cartilage has been shown to 
be subject to proteoglycan depletion as a result of several 
processes including the release of proteases and glycosidases 
from Type A cells (Hamerman et al., 1967), the release of 
similar enzymes by chondrocytes activated by the inflammatory 
process (Millroy and Poole, 1974), and the release of 
proteolytic enzymes from polymorphonuclear leucocytes (PMN) 
and the subsequent intracellular digestion of solubilised 
protoglycans within phagolysosomes of these cells (Weissman,
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1972). Depletion of proteoglycan from cartilage impairs its 
ability to rebound after removal of a deforming load, but 
permanent joint destruction only occurs as a result of 
collagen loss (Harris, et al. 1972; Harris and Krane, 1974).
Active RA is also accompanied by a great increase in the 
amount of synovial fluid and an elevation in total cell count. 
Normal synovial fluid does not clot due to the absence of 
fibrinogen. In the inflamed rheumatoid synovium fibrinogen 
passes from the plasma into the joints. There it can be 
activated to form fibrin. This protein may comprise as much 
as 34% of the total synovial fluid volume and may be 
responsible for the development of the classic articular 
manifestations of RA (Zvaifler, 1973; Jasani, 1979). The 
cellular composition of the synovial fluid is quite diverse. 
The majority of the cells (between 75% and 90%), are PMN, the 
remainder being comprised of 5-10% lymphocytes, some 
monocytes, macrophages and synovial lining cells, all of which 
may be involved in the pathogenesis of RA (Zvaifler, 1973).
1.4 EXTRA-ARTICULAR FEATURES OF RHEUMATOID ARTHRITIS
Although arthritis is the most frequent and prominent 
feature of RA, this disease is a systemic disease affecting 
m a n y  s y s t e m s  of the body. Of the e x t r a a r  ti cular 
manifestations perhaps the most common are subcutaneous 
nodules which appear in approximately 20-25% of patients.
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They are almost invariably associated with seropositive 
disease, that is, patients whose sera contain autoantibodies 
to immunoglobulin, which is associated with a more severe and 
destructive disease (Stage and Mannik, 1973). Areas subjected 
to mechanical pressure are common sites. Subcutaneous nodules 
seldom cause symptoms, but occasionally they break down or 
become infected. Histologically, the rheumatoid nodule is 
composed of a central area of necrosis surrounded by a 
palisade of epithelioid cells with variable degree of 
lymphocyte and plasma cell infiltration and vasculitis. The 
presence of immunoglobulin and complement in the necrotic 
areas has been demonstrated but may have little pathogenic 
significance in such a situation. If this immunoglobulin 
synthesis occurs in the nodule it may however be relevant to 
the p a t h o g e n e s i s  of the d i s e a s e  (Zvaifler, 1973). 
Morphological alteration in the structure of the blood vessels 
or vasculitis also occurs with considerable frequency. This 
may result from a number of factors, the deposition of immune 
complexes and fibrin, infiltration of the vessel wall with PMN 
and mononuclear cells and degradation of collagen and elastin. 
The clinical effects of vasculitis include skin lesions, 
peripheral gangrene and visceral lesions leading to 
dysfunction of the heart, gastro-intestinal tract, kidneys, 
brain, spinal cord and peripheral nerves (Maini, 1977). Other 
extra-articular features include muscle wasting, lymph node 
enlargement, , inflammation and distention
of the tendons and bursae, atrophy of the skin, splenomegaly
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and leukopaenia. Constitutional symptoms include malaise, 
fever and weight loss (Fye et al., 1979; Barnes, 1980).
1.5 IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS
Although the underlying reason for the persistent chronic 
inflammation of the synovial structures and extra-articular 
tissues in rheumatoid patients remains unknown, an increasing 
number of observations suggest that both cellular and humoral 
immunological events mediate its pathogenesis. Microscopic 
examination of the synovial membrane reveals dense collections 
of lymphocytes, plasma cells and macrophages in both diffuse 
and nodular patterns, a picture strongly reminiscent of an 
antigen stimulated lymph node. (Gardner et al., 1965). 
Rheumatoid synovium has been referred to as an ectopic 
lymphoid organ with large numbers of lymphocytes and plasma 
cells generating immunoglobulin. (Zvaifler, 1973, and Smiley 
et al., 1968).
1.5.1 Humoral immunity
Many systemic rheumatic diseases are characterised by the 
presence of one or more serum autoantibodies. Autoantibodies 
against the Fc fragment of immunoglobulin G molecules were 
first discovered in the sera of RA patients and hence have 
been named rheumatoid factors (RF's). RF's may be present in 
the IgG, IgM and IgA classes (Johnson, 1976). It is now known
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that RF's are detectable in the sera of many patients with 
non-rheumatic diseases and even in some normal individuals 
(Carson, 1982). In synovial fluid IgG RF predominates (Smiley 
et al., 1968). IgG anti-IgG may act as both antigen and
antibody with the ability to self-associate to form immune 
complexes (Pope et al., 1974). Self-association of IgG anti- 
IgG may occur extensively with the resulting complexes 
providing an inflammatory stimulus within rheumatoid joints 
and thus playing a major role in synovitis (Munthe and Natvig, 
1972; Male and Roitt, 1981). It may be postulated that immune 
complexes in the synovium could activate the complement 
cascade. The release of the chemotactic fragments C3a and C5a 
would promote migration of neutrophils, which together with 
synovial lining and pannus macrophages, would phagocytose the 
complexes. The subsequent release of lysosomal enzymes and 
cationic proteases may contribute to enzymic injury to the 
articular cartilage and further aggravate the inflammation. 
The local formation of IgG anti-IgG complexes would make the 
rheumatoid joint akin to an Arthus reaction (Maini, 1977). 
Immune complexes may also form in the bloodstream and 
subsequently localise in tissues. Such a pattern is seen in 
the acute and chronic models of serum sickness. Maini (1977) 
has suggested that the presence of complexes in the 
bloodstream might contribute to the multi-system features of 
RA, as well as vasculitis. Antibody synthesis is known to be 
controlled, at least partially, by feedback inhibition. The 
complexing of IgG RF may impair the negative feedback
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regulation of IgG synthesis in the plasma cells and could 
explain why they produce IgG RF at an apparently uncontrolled 
rate, leading to self-perpetuating immunologic and 
inflammatory processes (Natvig and Munthe, 1975). There is a 
good deal of evidence to support the suggestion that immune 
complexes are involved in the pathogenesis of RA. Complement 
component levels are reduced in synovial fluids in a majority 
of rheumatoid patients and are inversely correlated with 
immune complexes (Lunthra et al., 1975). Deposits of immune 
complexes have also been demonstrated in acutely inflamed 
vessel walls (McDuffie, 1978). Further evidence includes the 
localisation of immunoglobulin and complement in articular 
cartilaginous tissue of most RA patients (Cooke et al., 1975) 
and the presence of large inclusion bodies containing 
immunoglobulin and complement in the PMN of patients with 
Felty's syndrome (Andreis et al., 1978). A strong correlation 
between raised levels of IgG RF and vasculitis has been noted 
(Allen et al., 1981; Scott et al., 1981). In the latter study 
patients were found to have circulating complexes with anti- 
complementary activity, and serum C4 levels below the normal 
range, which indicated that the IgG-RF complexes bound 
complement.
1.5.2 Cell mediated immunity
The role of cell-mediated tissue injury may be no less 
significant than that which may be caused by antigen-antibody
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c o m p l e x e s .  Indeed, RA can o c c u r  in c o n g e n i t a l l y  
agammaglobulinaemic boys, where complexes presumably play no 
role at all (Taussig, 1979). There is also a predominance of 
T cells in the rheumatoid synovial membrane and T cell derived 
lymphokine like activity has been demonstrated in synovial 
fluids and supernatants of explants of inflamed rheumatoid 
synovial tissue (Stastny et al., 1975).
Lymphokines are soluble factors produced by the 
mononuclear cells that act as regulatory signals which 
modulate the activity of cells participating in the immune, 
inflammatory and reparative processes. It is not clear how 
many lymphokines there are since many appear to have multiple 
biological effects. The Second International Lymphokine 
Workshop (1979) made an attempt to define molecular entities 
rather than biological activities, which lead to the 
introduction of the term interleukins (IL). IL-1 and IL-2 
were distinguished by their biochemical properties and 
biological activities. Human IL-1 was defined as a 
macrophage-derived factor with a MW of between 12,000 and 
15,000 which enhanced lymphocyte proliferation while IL-2 was 
defined as a factor of 30,OOOMW which could support the 
continuous proliferation of cytotoxic T-cells - the inability 
of IL-1 to act as a growth factor for cytotoxic T-cells was 
the strongest evidence that IL-1 and IL-2 were different 
molecules. Larsson (1982) has suggested that these 
definitions were premature and Oppenheim and Gery (1982) have
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proposed that IL-1 possesses too many biological effects to be 
a single molecule. These workers have shown that IL-1 has 
important actions or several cell types in addition to 
lymphocytes. lL-1 appears to be similar if not identical to 
endogenous pyrogen and leucocyte endogenous mediator (LEM) 
(Sztein et al., 1981) LEM triggers the synthesis of acute 
phase proteins by hepatocytes (Kampschmidt, 1978). Several 
connective tissue cell types also respond to IL-1. 
Synoviocytes are stimulated to secrete collagenase and 
prostaglandins (Mizel et al., 1981), fibroblasts proliferate 
(Schmidt et al., 1981) and chondrocytes are activated to 
degrade the cartilage matrix (Jasin and Dingle, 1981). Thus 
IL-1 induces many cell functions that are relevant to the 
inflammatory process in general (fever, acute phase response) 
and to connective tissue in particular (synoviocytes, 
fibroblasts, chondrocytes activation. Any defect in the 
regulation of these cells could therefore lead to the immune 
and inflammatory aberrations characteristic of RA.
The pathogenic role of lymphoid cells in RA is emphasised 
by the achievement of clinical improvement with the use of 
treatments which are known to be immunosuppressive. Removal 
of immunoglobulins and immune complexes from plasma using 
p l a s m a p h e r e s i s  (Lockwood, 1979), the r e m o v a l  of 
immunocompetent lymphoid cells by thoratic duct drainage 
(Paulus et al., 1977), and total lymphoid irradiation (Kotzin 
et al., 1981), frequently lead to dramatic clinical
— 12 —
improvement. Together with these physical means of 
suppressing lymphocyte function the steroidal drugs, which 
have a wide range of actions including immune suppression, are 
extremely potent anti-inflammatory agents (Hart, 1979). These 
treatments may however defeat the object of the immune 
response and render the patient susceptible to many 
environmental pathogens.
1.6 AETIOPATHOGENESIS OF RHEUMATOID ARTHRITIS
The principal immunopathogenic features of RA may be due 
to a defect in immunoregulation either in isolation or related 
to a persistent antigen (Allison, 1977). Candidates for this 
initiating antigen include infectious agents, aggregated IgG 
and components of synovial tissue, cartilage and collagenous 
tissues (Paget and Gibofsky, 1979). Although an infectious 
cause for RA remains attractive, there is no consistent 
microbiological evidence available. However, bacteria are 
known to be the causative agents in reactive arthritis. This 
explosive monoarthritis, which occurs as a consequence of a 
distal infection, can be resolved with antibiotic therapy 
(Munoz, 1978). Similar changes to those occurring in the 
synovium and synovial fluid in RA are seen in Lyme disease 
(Steere et al., 1977). Immune complexes are also present in 
this systemic inflammatory disorder, although RF is absent 
(Hardin et al., 1979). Strong circumstantial evidence favours 
transmission of the causative agent by a minute tick,
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Ixodes dammini (Steere and Malawista, 1979). A spirochete has 
recently been isolated from these ticks and is under study as 
a potential aetiologic agent (Burgdorfer et al., 1982). Oral 
penicillin G or tetracycline may prevent or attenuate the 
subsequent arthritis (Steere et al., 1980). More attractive 
candidates for the causative agent of RA are viruses. The 
arthritis caused by viruses mimics some of the 
symptoms of RA. Onset is characterised by fever and malaise, 
the arthritis is usually symmetrical and affects the same 
spectrum of joints as RA. The major difference between the 
two disease states is that reactive arthritis is transitory 
and self-limiting (Van Sauter and Utsinger 1978). A possible 
association between RA and Eptein-Barr virus (EBV) has been 
proposed. EBV is a polyclonal B cell activator which is 
ubiquitous in the environment (Rosen et al., 1977). Alspaugh 
and Tan (1976) and Alspaugh et al. (1978) have demonstrated 
that the sera of approximately 65% of RA patients react with 
cell associated nuclear antigen present in Wil2 human lymphoid 
cell lines induced by EBV infection compared to low levels of 
the antibody in normal healthy controls. This RA associated 
nuclear antigen (RANA) appears to be distinct from Epstein- 
Barr nuclear antigen (EBNA) (Alspaugh et al., 1978). Catalano 
et al., (1980) studied healthy individuals and showed that 
those having antibodies to viral capsid antigen (VGA), which 
is expressed during EBV infection, also had anti-RANA 
antibodies, while anti-VGA negative individuals were anti-RANA 
negative. They concluded, therefore, that anti-RANA
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antibodies are produced only after EBV infection. Lymphocytes 
from both normal and RA individuals can be stimulated in vitro 
to produce IgM RF by EBV infection (Slaughter et al., 1978). 
A similar production of IgM RF following injection of 
bacterial lipopolysaccharide in mice has been reported 
(Dresser, 1978). It may be proposed that naturally occurring 
B cell activators, such as EBV, may initiate the stimulation 
of clones of cells in vivo which would react with autoantigens 
and result in elevated levels of autoantibodies including RF. 
Any involvement of EBV in the pathogenesis of RA must however 
remain speculative (Depper and Zvaifler, 1981), particularly 
when the polyclonal nature of this stimulus is compared with 
the restricted spectrum of autoantibodies, largely 
antiglobulins, detected in RA patients.
1.6.1 Immunogenetics
The difficulty in determining initiating factors may be 
due to the possibility that such factors are environmental 
agents which do not normally induce disease but which in 
genetically susceptible individuals may do so by interacting 
abnormally with the immune system. The interest in the 
influence of genetics on the aetiopathogenesis of rheumatic 
diseases has been stimulated by the work of Brewerton et al. 
(1973), who demonstrated a strong association between 
ankylosing spondylitis and the presence of HLA-B27. A 
relatively high risk of predisposition to RA has been observed
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in HLA-DR4+ compared to DR4- individuals (Stastny, 1978; 
Panayi et al., 1976). The precise links between these genetic 
markers and the pathogenic mechanisms underlying each disease 
are still unclear. It has recently been suggested (Jones et 
al., 1983) that HLA-DR4 is a marker of likely disease severity 
in RA rather than of susceptibility to arthritis. This is 
consistent with the observation that patients with extra- 
articular manifestations of severe RA are almost all HLA-DR4W 
positive (Dinant et al., 1980).
1.7 IN VITRO STUDIES OF THE IMMUNE RESPONSE IN RHEUMATOID 
ARTHRITIS
Much of the research aimed at determining whether or not 
a defect in immunoregulation exists in RA has been directed 
towards the peripheral blood mononuclear cells (PBMC). These 
cells are more readily available from both healthy controls 
and rheumatoid patients than synovial tissue. Although there 
are many conflicting reports it is generally accepted that 
normal T- and B-lymphocyte proportions exist in the peripheral 
blood of rheumatoid patients (Paget and Gibofky, 1979). 
Earlier studies of cellular immunity based on skin testing to 
common antigens showed significant abnormalities in patients 
with RA. Waxman et al. (1973) found that 42% of RA patients 
were completely anergic to five common antigens. Another 
common estimate of the functional status of PBMCs used in 
recent years has been cell proliferation in response to a
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mitogens such as concanavalin A(ConA) or phytohaemagglutinin 
(PHA). Studies of the mitogenic response of PBMCs from RA 
patients have not revealed consistent results from one 
laboratory to another. Some investigators have reported no 
significant differences between rheumatoid patients and 
controls (MacLaurin 1971; Reynolds and Abdou, 1973; Kinsella, 
1974). Others have noted some very low responses among RA 
patients but have reported normal mean values (Denman et al., 
1973; Kacaki et al., 1969; Waxman et al., 1973.). Still 
others have reported generally low responses in RA (Griswold 
and McIntosh, 1973; Lance and Knight, 1974; Lockshin et al., 
1975; Highton et al., 1981). These discrepant reports might 
be explained by the heterogeneity of the patients studied and 
differences in the methodological approach of various 
investigators. It has been proposed that there are indeed 
decreased responses in patients with RA but this response is 
limited to a subset of patients characterised by the presence 
of erosive joint disease (Silverman et al., 1976). In more 
recent years lymphocyte proliferation assays have been 
superceded by in vitro pokeweed mitogen (PWM) stimulated 
production of immunoglobulin, measured using an enzyme-linked 
immunosorbance assay (ELISA). A number of workers have 
reported reduced levels of immunoglobulin production by PBMCs 
obtained from RA patients compared to healthy controls 
(Alarcon et al., 1982; Poikonen et al., 1982; Plater-Zyberk et 
al., 1983). The anergic reactions of RA patients to common 
antigens and the hyporesponsiveness of rheumatoid mononuclear
— 17 —
cells in culture may seem a paradox considering the nature of 
the disease. RA is a disease in which the immune response is 
hyperactive, and one might expect the opposite to occur. 
Possible explanations for this depressed immune response in RA 
include preoccupation of the immune mechanisms of the host 
with reactivity related to the pathogenesis of the disease, 
viral infections or immune complexes.
1.8 CHEMOTHERAPY IN RHEUMATOID ARTHRITIS
1.8.1 Non-Steroidal anti-inflammatory drugs
The mode of action of many of the drugs used in RA may 
involve the manipulation of one or more components of the 
immune system. As has been previously stated, treating RA by 
simply suppressing the immune system is undesirable. Lacking 
a cure for RA any treatment must be empirical and this is 
initially to treat the symptoms. The non-steroidal anti­
inflammatory drugs (NSAID) do not cure or permanently reverse 
the inflammatory process in any arthropathy, but by reducing 
swelling and pain and allowing better joint function, do help 
the clinical condition considerably (Hart et al., 1981). 
NSAID are to a greater or lesser degree anti-inflammatory 
analgesic and antipyretic. Aspirin and the salicylates are 
the most widely used of the NSAID and have been used in 
medicine since 1899. Indomethacin and phenylbutazone followed 
and more recently large numbers of drugs based on different
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organic acids such as propionate and phenylacetate. Vane 
(1971) proposed that the NSAID act as anti-inflammatory agents 
by inhibiting prostaglandin (PG) synthesis. They interact 
directly with the enzyme, cyclooxygenase and inhibit the 
synthesis of all PGs. In vi t r o all NSAID are active 
inhibitors of cyclooxygenase (Crook et al., 1976). As well as 
their beneficial effects they may also produce toxic side 
effects on the gastrointestinal tract. PGs promote pain 
(Ferreira, 1978), fever (Feldberg et al., 1972), swelling 
(Wedmore and Williams, 1981) and may have a protective effect 
on the gastric mucosa (Rainsford, 1982), all of which appears 
to support Vane's hypothesis. However, while clinical 
experience suggests that, in general, the NSAID are equally 
effective in patients, their potencies as cyclooxygenase 
inhibitors vary widely (Crook et al., 1976). Salicylate, 
which has little effect on PG synthesis, is clinically 
indistinguishable from aspirin. Also, cyclooxygenase activity 
in rheumatoid synovial tissue may be abolished in patients 
taking low doses of aspirin (600 mg day” )̂ which do not exert 
detectable antiinflammatory effects. PGs are a family of 
compounds and have also been shown to have anti-inflammatory 
(Kunkel et al., 1981) and immunosuppressive (Goodwin et al., 
1977) effects. PGs can modulate each other directly and are 
also self-modulating via the cyclic nucleotides (Dunn et al., 
1976). The PGs also interact with other mediators of 
inflammation (Trang, 1980). It is unlikely, therefore, that 
suppression of PGs is the unique site of action of the NSAID.
— 19 —
Moreover, it is perhaps unwise to block completely the 
production of such an important group of physiological 
mediators.
1.8.2 Second-line anti rheumatic drugs
NSAID merely treat the symptoms leaving the long term 
course of the disease unchecked. If the disease does progress 
another group of drugs variously termed second line, 
antirheumatic, disease modifying, remission inducing, may be 
used. These agents differ from classical anti-inflammatory 
drugs in that they appear to have the capacity to modulate the 
course of RA and, in some cases, to induce remission of the 
disease. The most successful anti-rheumatic agents represent 
the outcome of shrewd clinical observations in the use of 
compounds introduced for other diseases rather than the result 
of systematic research on the part of the pharmaceutical 
industry.
1.8.3 Gold compounds
In the early 1920s the similarity between RA and 
tuberculosis and the ability of gold to inhibit the growth of 
tubercle bacilli in culture prompted physicians to treat 
rheumatoid patients with gold salts that had been employed, 
erroneously, in the management of tuberculosis (Bird and 
Wright, 1982). That gold salts have survived since their
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introduction in the 1920s may be seen as either a tribute to 
their effectiveness, or a reflection of the absence of a truly 
antirheumatic drug. A number of controlled clinical trials 
have established that gold compounds are effective in the 
treatment of RA (Research Sub-committee of the Empire 
Rheumatism Council, 1960; Research Sub-committee of the Empire 
Rheumatism Council, 1961; Co-operating Clinics Committee of 
the American Rheumatism Association, 1973) and can modify the 
course of the disease as judged radiologically. The mode of 
action of gold compounds however, remains unknown.
Aurothiomalate has been shown to inhibit several lysomal 
and other cellular and extra-cellular enzymes (Persellin and 
Ziff, 1966; Janoff, 1970; Naccache et al., 1977). These 
enzymes may be inhibited intracellularly in vivo, as elemental 
gold is concentrated in the reticuloendothelial system 
(Gottlieb et al., 1972) and may be readily detected within 
phagocytic cells in rheumatoid synovial tissue (Vernon-Roberts 
et al., 1976; Nakamura and Igaraski, 1977). In vitro the 
effects of gold compounds on the immune system have been 
investigated in several assay systems. Aurothiomalate has 
been been shown to inhibit complement activation in vitro 
(Schütz et al., 1974; Burge et al., 1978). Both these effects 
are mediated by the gold component of the drug. The actions 
of gold compounds on mononuclear cell function are more 
complex. In vitro, gold has been shown to suppress antigen 
and mitogen driven lymphocyte proliferation (Lipsky and Ziff,
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1977; Lies et al., 1977). Lipsky and Ziff (1977, 1982) have 
proposed that this effect is caused by inhibition of monocyte 
accessory function in the culture system. These observations 
in vitro contrast with studies carried out with PBMC from RA 
patients being treated with aurothiomalate, in whom a good 
clinical response is accompanied by a change in lymphocyte 
responsiveness from a depressed state to normal (Davis et al., 
1979, Highton et al., 1981).
1.8.4 D-Penicillamine
On equally slender and highly empirical grounds, D- 
penicillamine (D-pen) has been similarly used in the treatment 
of RA. D-pen is 2,2'-dimethyl cysteine, a degradation product 
of penicillin, and named penicillamine by Abraham and 
associates (1943). D-pen is used in the treatment of three 
unrelated disorders, Wilson's Disease, cystinuria and RA 
(Lyle, 1979). The usefulness of D-pen in the treatment of 
patients with RA has been well established (Multicentre Trial 
Group, 1973). Its actions are slow and selective since it 
does not benefit all types of inflammatory arthritis. D-pen 
exerts its effects on extraarticular features of the disease, 
as well as on the joints, and there is often reduction in RF 
and erythrocyte sedimentation rate (ESR). In patients able to 
continue treatment, there is improvement in the outcome of the 
disease as judged by delay in radiological progression. The 
mode of action of the drug is unknown. It was first used
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because of its ability to reduce titres of RF (Jaffe, 1970), 
but this is almost certainly not its mode of action. In vitro 
studies by other investigators have demonstrated the capacity 
of this compound and other thiols such as 2-mercaptoethanol 
(2-ME) to dissociate macroglobulins by cleavage of their 
inter-subunit disulphide bonds. It is however unlikely that 
the reduction of circulating RF titres results directly from 
the action of D-pen, since the concentration of D-pen attained 
in vivo is orders of magnitude less than that needed to 
dissociate macroglobulins (Van de Stadt et al., 1979). These 
in vitro studies do however illustrate one important aspect of 
D-pen's interactions with body tissue, namely sulphydryl 
disulphide exchange.
Another feature of D-pen is its ability to chelate metal 
ions, including copper (Lyle, 1979). These observations 
explain the use of this drug in treating cystinuria and 
Wilson's disease, but their significance for the actions of D- 
pen in RA remains obscure. D-pen enhances serum sulphydryl- 
disulphide interchange reactions (Hall and Gillan, 1979) and 
dissociates IgA-alpha, antitrypsin complexes in vivo (Wollheim 
et al., 1979). In vitro D-pen inhibits the sulphydryl 
dependent heat dénaturation of IgG (Gerber, 1978) and might 
therefore prevent the formation of autoantigenic IgG 
aggregates in v ivo. The scavenging of free radicals, 
associated with the formation of aggregated IgG by D-pen may 
result in a similar effect (Wickens et al., 1983). Copper-D-
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pen complexes have been shown to express superoxide dismutase- 
like activity, although at relatively high concentrations 
(Greenwald, 1981). Thiol compounds, including D-pen, have 
been shown to be potent inhibitors of myeloperoxidase activity 
(Matheson, 1982) which could contribute to protection of 
tissue from oxidative damage (Rosen and Klebenoff, 1979).
In-vitro studies involving the effects of D-pen on cell 
function have often produced conflicting and ambiguous 
results. This is probably due largely to the difficulty in 
determining a realistic level of the drug due to use in 
culture. Chwalinska-Sadowska and Baum (1976) have reported 
inhibition of chemotaxis by D-pen whereas Mowat (1978) has 
failed to demonstrate this effect. D-pen has also been 
reported to have a biphasic effect on lymphocyte responses to 
mitogens, with "low" doses enhancing the responses and higher 
doses resulting in suppression (Maini and Roffe, 1976). Lipsky 
and Ziff (1982) have shown that whilst D-pen alone causes a 
modest decrease in mitogen-induced lymphocyte proliferation 
the addition of copper salts to D-pen containing cultures 
results in a marked augmentation of the degree of inhibition. 
Thus, whilst an immodulatory effect of D-pen seems likely, 
exactly what that effect is remains unclear.
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1.9 THE ROLE OF SH GROUPS IN RHEUMATOID ARTHRITIS
1.9.1 Sulphydryl compounds as anti-rheumatic drugs
It is interesting to note that many of the second line 
antirheumatic drugs are either thiol compounds or are 
converted to thiol compounds in vivo (Hunneyball, 1980). D- 
pen is a thiol and Munthe (1978) has observed that all the 
gold salts examined in controlled long term studies have been 
thiols. Levamisole is an antirheumatic compound which has 
been shown to possess second-line antirheumatic actions in 
double-blind studies (Multicentre Study Group, 1978, Symoens 
and Schuermans, 1979). The drug is now rarely used in RA 
because of toxic side effects (Symoens et al., 1979). 
Levamisole has a number of effects on mononuclear cell 
function both in vitro and in vivo that has led to its being 
called "immunorestorative" and "thymomimetric" (Symoens and 
Rosenthal, 1977). Its clinical and biological effects are 
similar to those of gold and D-pen (Symoens and Schuermans, 
1979). Levanisole is extensively metabolised in vivo, a major 
p r o d u c t  being D L -2-oxo-3-(2-mercaptoethy1 - 5 -p h e n y l - 
imidazolidine) (OMPI) which contains a free thiol group (De 
Brabander et al., 1978). Jaffe (1980) has suggested that 
these sulphydryl (SH) compounds are the first of a new 
g e n e r a t i o n  of a n t i - r h e u m a t i c  drugs and that their 
effectiveness may be due, at least in part, to their SH 
moiety.
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Fig. 2. Structural formulae of Auranofin, D-pen 
and Levanisole.
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1.9.2 Sulphydryl levels in rheumatoid patients
Abnormally low SH levels are found in RA serum (Lorber et 
al., 1964) and serial measurements show an inverse correlation 
with disease activity (Haataja, 1975). A similar depression 
in erythocyte cell surface SH groups has been shown to 
correlate with serum SH levels (Lorber and Chang, 1968). It 
is not clear whether this disturbance in thiol expression 
plays a role in the pathogenesis of RA. However, Hall et al. 
(1981) have shown that following treatment with D-pen and 
aurothiomalate, serum SH levels rose to normal values in good 
clinical responders.
In plasma the vast majority of SH groups are present on 
the albumin molecules and the normal albumin thiol 
concentration is about 0.7 thiols per albumin molecule 
(Foster, J.F., 1977). The reason for this non-integral number 
arises because some thiols are blocked by the formation of a 
disulphide bond between the albumin thiol and small SH 
compounds such as cysteine, and the depression of serum SH in 
RA appears to be due to further oxidation and subsequent mixed 
disulphide formation (Thomas and Evans, 1975). Hall et al., 
(1984) has proposed that free radicals produced during the 
inflammatory processes are responsible for promoting this 
reaction. During acute inflammation there is a general 
alteration of liver protein synthesis, the acute phase 
response, and a decrease in albumin synthesis occurs in order
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to allow for the rapidly increased synthesis of a number of 
substances, collectively known as the acute phase reactants, 
that play an essential role in host defence (Sipe and 
Rosenstreich, 1981). This decrease in albumin concentrations 
is obviously a partial cause of decreased thiol levels in RA, 
but the lack of a good correlation between albumin and thiol 
concentrations suggests it is not a major effect (Banford et 
al., 1982). Caeruloplasmin is an acute phase reactant which 
rapidly oxidises some low molecular weight thiols such as 
cysteine and thiomalic acid to disulphides (Albergoni and 
Cassini, 1978). It does not affect the thiol of albumin 
directly presumably because of steric hindrance between the 
two proteins. However, low molecular weight disulphides 
exchange readily with the thiol of albumin (Foster, 1977) and 
therefore, the production of di sulphides by caeruloplasmin 
could be a determining factor in the reduced thiol 
concentration. Alternatively, or in addition to this, the 
release of hydrogen peroxide singlet oxygen, and hydroxyl 
radicals, from stimulated neutrophils and macrophages, may 
play a role in the decreased SH levels (Badwey and Karnovsky, 
1980; Hall et al., 1984).
1.9.3 Immunomodulation by thiol compounds
Whatever the cause of the blocked serum and cell surface 
SH groups in RA it may have a profound effect on the
- 28 -
pathogenesis of the disease. SH groups are a highly reactive 
species with important functions in several biological 
processes including inflammation and the immune response 
(Jensen, 1959). In animal studies, several aspects of the 
immune response have been shown to involve SH groups. Simple 
thiols such as 2-ME has been shown to potentiate the function 
of many immunological cells in vitro, including antibody 
responses (Click et al., 1972), lymphocyte proliferation 
(Broome and Jeng, 1973; Bevan et al., 1974), cytotoxic T-cell 
responses (Cerottini et al., 1974; Harris et al., 1976; 
Igarashi et al., 1977) and the growth of B-lymphocyte colonies 
(Metcalf, 1976). Click et al. (1972) found that the addition 
of 2-ME at an optimal dose of 2 x 10”^M resulted in a marked 
increase in the plaque forming cell response of unfractionated 
spleen cells. These authors concluded that this effect was 
not due to cell viability because the reagent did not need to 
be added daily to the culture. Rather, they postulated that 
2-ME was exerting its effects on a very early event since the 
half-life of the reducing agent was very short. Chen and 
Hirsch (1972) examined the action of 2-ME on the plaque 
forming cell response of spleen cells depleted of adherent 
cells. They showed that the depletion resulted in a marked 
reduction of the antibody response and that the addition of 
peritoneal macrophages or 2-ME would reconstitute it. It is 
therefore often stated that 2-ME can substitute functionally 
for macrophages. The critical point is a question of whether 
the response of T- and B-cells to SRBC in the presence of 2-ME
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is truly macrophage independent. Hodes and Singer (1977) 
showed that when accessory cells were functionally depleted by 
adherence using Sephadex G-10 columns, there was a strict 
dependence of accessory cells without any effect whatsoever of 
2-ME. These results confirm those of Erb and Feldmann 
(1975abc). Rosenstreich and Mizel (1978) demonstrated that 2- 
ME enhanced the activity of very small numbers of macrophages 
added to the culture and concluded that 2-ME synergised with 
macrophages to increase the response.
It is not known whether in the above systems 2-ME is 
acting directly on the cell or through a secondary product. 
Broome and Jeng (1973) made a very thorough analysis of the 
effect of various thiols on the growth of normal spleen cells 
and various lymphoid tumour lines. Normal spleen cells and 13 
of 22 tumour lines had increased growth in cultures when the 
various thiols were added. In contrast, other cell lines 
including HeLa and fibroblasts were not affected by 2-ME. 
Reactions involving SH groups can therefore markedly affect 
both lymphocytes and monocytes.
The growth of the mouse lymphoma cell line L12.10/F10.30 
is dependent on the presence of either a thiol or macrophages. 
This lymphoma may represent cells that have retained some of 
the regulatory mechanisms of the normal lymphocyte (Hewlett et 
al., 1977). This would suggest that the mode of action of 
macrophages in its accessory role is, at least in part, via
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the SH group. Experimental evidence has shown that 2-ME or 
macrophages do not act directly on the lymphoma cells but on a 
serum factor. The macrophage activated serum factor (MaSF) is 
thought to be albumin (Hewlett, personal communication, 1981). 
Albumin is known to be essential for the growth of lymphocytes 
in culture (Polet and Spieker-Polet, 1975; Spieker-Polet and 
Polet, 1976; Arai et al., 1977). Hewlett (personal 
communication, 1981), proposed that MaSF exists in two forms, 
an inactive form (pro-MaSF) and an active form (MaSF). They 
postulated that pro-MaSF was albumin and MaSF mercaptalbumin. 
The addition of 2-ME, and presumably macrophages, reduced the 
albumin to mercaptalbumin, which they suggested was necessary 
for the immune response to take place (Fig. 3). MaSF thus 
provides one mechanism whereby macrophages may modulate the 
immune response via an SH reaction. It is not known whether 
these observations have any relevance to normal immune 
responses in humans. It may be speculated that if it does, 
the blocked SH groups present in RA contribute to the 
abnormalities in the immune response in this disease. In 
experiments with normal lymphocytes in culture, there is 
considerable evidence to suggest that the effects of low 
molecular weight thiols on lymphocyte activity are mediated by 
cell surface SH groups and not by intracellular thiols or by 
secondary mediators. Glutathione, an impermeant thiol, has 
been shown to enhance lymphocyte proliferation in a similar 
manner to 2-ME, whereas cysteamine phosphate, a compound 
containing no free SH groups until it is dephosphorylated
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Fig. 3. Flow diagram to illustrate the MaSF 
hypothesis. Pro MASF is activated to MaSF by its 
oxidation - either by a thiol compound or a 
MaSF is necessary for ac t i v a t i o n  of the 
lymphocyte.
- 3 2 -
within the cell, does not (Noelle and Lawrence, 1979). 
Furthermore, it has been demonstrated that lectin-induced cell 
proliferation can be inhibited by blocking the free SH groups 
on the cell surface (Chaplin and Wedner, 1978).
Abnormally low serum SH levels are a feature of active RA 
and following their successful treatment with sulphydryl drugs 
the SH levels return to normal. The immune system is 
intimately involved in the pathogenesis of RA, and can be 
influenced by thiols. The aim of this project was to 
determine the possible role of SH groups in immunoregulation 
and to determine whether they might be involved in the 
immunopathogenesis of RA. In particular it was hoped to 
identify the ways in which D-pen might modulate the immune 
response in RA patients, and thereby exert both its anti­






All reagents and disposable 
tissue culture plastics, 
except where otherwise 
stated :
Gibco Bio-cult Limited, 
Paisley, Scotland.
All chemicals, except where Sigma Chemical Company
otherwise stated: Limited, Poole.
Ficoll-paque, Percoll, Pharmacia (GB) Limited,
Sephedex G-10, Sepharose 6B: Milton Keynes.
IL-1 and IL-2 standards: Koch-Light Limited, Suffolk,
Scintillation grade toluene: British Drug Houses (BDH) 
Limited, Poole.
Scintillation vials: Richardsons of Leicester, 
Leicester.
Visking dialysis tubing: Medicell International 
L imi ted, London.
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2.2 EQUIPMENT SUPPLIER
MSE Chilspin 2 Centrifuge: MSE Scientific Instruments,
Sussex.
Skatron cell harvester; Flow Laboratories Limited, 
Irvine, Scotland.
Laborlux 12 microscope: E. Leitz (Instruments) 
Limited, Luton.












Patients were assessed by either Dr. P. Maddison or 
Dr. A. Woolf. Patients designated RA-NSAID had sero-positive 
disease with active sinovitis and were receiving NSAID therapy 
only. Patients designated RA-D-pen were those who responded 
well to D-pen therapy. Healthy controls were age and sex 
matched with patients.
2.4 ROUTINE BUFFERS AND MEDIA




Disodium hydrogen phosphate 11.50
Potassium dihydrogen phosphate 2.00 pH 7.3
The above were dissolved in 1 d m “  ̂ distilled water, 
filter sterilised (Millipore filter 0.45 pm pore size) and 
stored at until required.
Before use, the solution was diluted to ten times its 
volume with distilled water. To this was added the equivalent 
of : -
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0.1 g.dm  ̂ calcium chloride 
0.1 g.dm“  ̂magnesium chloride
The pH was corrected to 7.3 with IM sodium hydroxide 
solution.





Potassium dihydrogen phosphate 0.60
Disodium hydrogen phosphate 0.48 pH 7.3
The above were dissolved in 1 dm^ distilled water, filter 
sterilised, and stored at 37°. Before use, a 10 fold dilution 
was performed with distilled water and the pH corrected to 7.3 
with IM sodium hydroxide.
2.4.3 Ammonium chloride solution
This solution was used for the lysis of extraneous red 




Potassium hydrogen carbonate 1.000
Ethelenediaminetetracetic acid 0.004
The above constituents were dissolved in 1 dm^ distilled 
water and the pH corrected to 7.4 with IM sodium hydroxide.
2.4.4 Lymphocyte culture medium RPMI 1640
Volume ( an^ )
RPMI 1640 (xlO strength) 10.00
Penicillin and Streptomycin solution
5000IU cm”3 of 2.00
200 mM glutamine 2.00
7.5% sodium bicarbonate 2.70 pH 7.4
Foetal calf serum 10.00
The above mixture was diluted to 100 cm^ with sterile, 
distilled water. The pH was corrected to 7.4 with sterile IM 
sodium hydroxide.
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Sodium azide 0.20 pH 9.6
The constituents were dissolved in sterile, distilled 
water and the solution stored at room temperature for not more 
than two weeks.
PBS/Tween
Tween 20 (Polyoxyethylene sorbitan
monolaurate) 0.5 cm^
Sodium azide 0.2 g
The above constituents were added to 1 dm^ PBS and the 
buffer stored at room temperature.
Diethanolamine buffer (10%)
Diethanolamine 97 cm^
Distilled water 800 cm^
Sodium azide 200 mg
Magnesium chloride hexahydrate 100 mg
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The above constituents were mixed and adjusted to pH 9.8 
with IM hydrochloric acid. The total volume was made up to 
Idm^ with distilled water and the buffer stored in an amber 
bottle at room temperature.
2.4.6 Scintillation fluid
To 2.5 dm^ of toluene was added:-
12.50 g 2,5 - Diphenyloxazole (PPO)
0.75 g 1,4 - Di-2-(4-methyl-5-phenyloxazolyl)
benzene (POPOP)
2.5 HUMAN CELL PREPARATION
PBMC were prepared from heparinised peripheral blood, 
diluted with an equal volume of CMFSS, and by density 
flotation on Ficoll-Paque (Boyum, 1968). 7 cm^ of diluted
blood was layered onto 3 cm^ of Ficoll-Paque in sterile 
pi^L^^c^centrifuge tubes. The tubes were then centrifuged at 
for 30 minutes. The PBMC was removed from the 
interface, washed three times with CMFSS and resuspended in 1 
cm^ RPMI 1640. The cells were counted in an haemocytometer 
and then diluted with RPMI 1640 to give 10^ cm “ .̂ In some
experiments PBMC were further separated into monocyte and
lymphocyte-enriched fractions by centrifugation through 52% 
v/v Per coll. PBMC in 1 cm^ of RPMI 1640 were layed onto 2 cm^
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of 52% Percoll in sterile plastic centrifuge tubes. The tubes 
were centrifuged at for 30 minutes. After
centrifugation, monocytes (greater than 90% pure by 
morphology) were obtained from above the Percoll layer and 
lymphocytes from the pellet. The latter were depleted of any 
residual monocytes by passage through a 10 ml column of 
Sephadex GIO (Pharmacia) equilibrated with CMFSS containing 5% 
FCS. The various cell populations were washed three times 
with CMFSS and resuspended in RPMI 1640 and counted. All 
tissue culture experiments were carried out using aseptic 
techniques.
2.6 HUMAN CELL CULTURE AND ASSAY TECHNIQUES
2.6.1 IgG Production
The PBMC, monocytes and lymphocytes were cultured alone 
or in various combinations using standard conditions. PBMC or 
lymphocytes (10^ cm”^) were cultured in 0.2 cm^ aliquots of 
RPMI 1640 containing 10% FCS in flat-bottom microtitre plates. 
Incubations were set up in the absence or presence of PWM 
(final dilution 1:1000). After culture for 14 days at 37C in 
a humidified atmosphere of 5% CO2 in air, the supernatants 




PBMC (10^ cm~3) were cultured in 0.2 cm^ aliquots of RPMI 
1640 containing 10% FCS in round bottomed microtitre plates. 
Cultures were set up in the absence or presence of PHA, 1 pg 
cm” .̂ The cells were incubated for 72 hours at 37C in a humid 
atmosphere of 5% CO2 in air. 4 hours before termination of 
the incubation the cells were pulsed with 0.5 nCi, tritiated 
thymidine (specific activity 5 ci mm o l ”^). The cells were 
harvested onto flass fibre discs and dried. These were then 
placed into vials containing 2 cm^ scintillation fluid and 
the uptake of radioisotope determined by liquid scintillation 
spectrometry.
2.6.3 Enzyme-linked immunoabsorbance assay (ELISA) for IgG
0.2 cm^ of an optimal dilution of a goat anti-human 
polyvalent immunoglobulin was dispensed into each ELISA 
cuvette well. The cuvettes were incubated in a humid box for 
1 hour at 37C and subsequently overnight at 4C. They were 
washed extensively with PBS/Tween, the final wash being 
aspirated with a mechanical pump. 0.2 cm^ of each doubling 
dilution of the control serum or test supernatants (in 
PBS/Tween) was added (in duplicate) to the cuvettes, which 
were subsequently incubated in a humid box at 37C for 1 hour. 
After incubation, the washing procedure with PBS/Tween was 
repeated. 0.2 cm^ of an optimal dilution (in PBS/Tween) of
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the phosphatase conjugated anti-human IgG was added to each 
cuvette and the plates incubated at 37C for 1 hour in a humid 
box. After extensive washing with PBS, 0.2 cm^ alkaline 
phosphatase substrate solution (p-nitrophenol phosphate) in 
ethanolamine buffer (Img cm~^) was added to each cuvette. The 
colour was allowed to develop at room temperature and when the 
positive control serum reached an absorbance value of 2.0 at 
405 nm, the reaction was stopped by the addition of 0.2 cm^ 
1.5M NaOH. The optical density of each cuvette was then 
determined at 405nm. The level of IgG synthesis was 
calculated by reference to a calibration curve obtained from 
known amounts of IgG in the assay system.
2.6.4 Serum SH assay
Serum samples were stored at -20C before use. 0.05 cm^ 
of serum was diluted with 0.75 cm^ of PBS and reacted with 0.2 
cm^ of freshly prepared 5,5'-dithiobis (2-nitrobenzoic acid) 
(DTNB) solution (2mM) for 5 minutes at 37C. The absorbance at 
440 nm. were measured against a serum blank. This value was 
converted to a serum SH concentration by reference to a 
calibration curve obtained from known amounts of reduced 
glutathione in the assay system.
2.6.5 Cell surface SH assay
6,6' dithiodinicotinic acid (6,6'-D) blocks cell surface
— 44 —
SH groups but does not penetrate the cell (Mehrishi and 
Grassetti, 1969). The mixed disulphide formed between the 
cell thiols and 6,6'-D can be split by treatment with a thiol 
such as glutathione with the subsequent release of thione into 
the supernatant. This can be measured spectophometrically at 
344 nm. and used to determine the number of SH groups on the 
cell surface.
20 X 10^ PBMC in 0.2 cm^ CMFSS were treated with 6,6'-D 
at 37C for 5 minutes. The cells were washed three times and
resuspended in 0.2 cm^ CMFSS. The treated cells were then
allowed to react with 10”  ̂ M. glutathione to release the 
thione, bound to the cell surface, into the supernatant. The 
cell suspensions were centrifuged and the supernatants 
collected. The amount of thione released was measured 
spectrophotometrically at 344 nm. The amount of surface SH 
groups present was calculated by reference to a calibration 
curve obtained from known amounts of reduced glutathione in 
the assay system.
2.6.6 Blockade of serum SH groups
Serum from healthy human controls was treated with a 
range of concentrations of iodoacetamide (lOA) for 1 hour at 
37C to block the SH groups. Excess lOA was removed by
dialysis against CMFSS overnight at 4C.
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2.6.7 Blockade of cell membrane SH groups
Cell surface SH groups were blocked by preincubating the 
cells for 1 hour at 37C with an irreversible non-penetrating 
SH blocking agent, p-hydroxymer cur i phenyl su Iphona te (PHMPSA) 
(Tsan and Berlin, 1971). The cells were then washed three 
times with CMFSS and resuspended in RPMI 1640.
2.6.8 IL-1 Production
Monocytes were separated from PBMC by centrifugation on 
52% Percoll as previously described. Monocytes (10^) were 
incubated in 1 cm^ of RPMI 1640 containing 10% FCS and 1 ^g of 
LPS for 24 hours at 37C, in the presence or absence of 2-ME (5 
X 10~^M). The supernatants were then collected and stored at 
- 20C prior to IL-1 assay.
2.6.9 IL-1 Assay
3-6 week old CgH/HeJ mouse thymus tissue were finely 
minced in DAB containing 2% FCS and dispersed by passage 
through a sterilised nylon screen. Large fragments were 
removed and discarded. Adherent cells were removed by passage 
through a Sephadex GIO column prewarmed at 37C. The cell 
suspension was washed three times in DAB/2% FCS at 4C. 0.1
cm^ aliquots of test supernatants were added in doubling 
dilutions to flat-bottomed microtitre plates. Cells (10^ in
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0.1 cm^ of RPMI 1640 containing 1% FCS, 5 x 10“  ̂M 2ME and 3 
pg PHA) were incubated with tritiated thymidine (5 cim mol~^) 
at 37C for 68 hours and then were pulsed for 4 hours. After 
harvesting the amount of thymidine uptake was used as an 
estimate of cell proliferation. The capacity of each of the 
test supernatants to induce cell proliferation was calculated 
using probit-analysis and the results plotted on an arbitrary 
scale of 1-100 units.
2.6.10 Production of IL-2
PMBC (10^ cm"3) were incubated in RPMI 1640 containing 
10% FCS and 1 mg cm“  ̂PHA in a humidified atmosphere of 5% CO2 
in air at 37C for 24 hours. At the end of the incubation 
period the cells were washed three times in RPMI 1640, 
resuspended and incubated similarly for another 24 h without 
PHA or FCS in 1 cm^ lymphocyte culture tubes. The tubes were 
then centrifuged at 2,000 rpm for 15 min and the supernatants 
collected. The supernatants were frozen at - 20C prior to 
assay.
2.6.11 Assay for IL-2 activity
Normal human PBMC activated with PHA were maintained in 
culture for at least 2 weeks in RPMI 1640 supplemented every 4 
days after the first week in culture with both FCS and lectin- 
free IL-2. The cells were used 4 days after the last addition
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of IL-2 for the assay of IL-2 activity. They were washed in 
CMFSS and placed in microtitre plates (10^ cells in 0.2 cm^ 
RPMI 1640 with 10% FCS). The supernatants being tested were 
added at eight doubling dilutions. The plates were incubated 
at 37C for 48 hours. Controls with resting cells were 
included and all assays were carried out in triplicate. IL-2 
activity was measured by the ability of test supernantants to 
induce cell proliferation. The capacity of each of the test 
supernatants to induce cell proliferation was calculated using 
probit-analysis and the results plotted on an arbitrary scale 
of 0-100 units.
2.7 RAT CELL PREPARATION
PVG rats were injected in the base of the tail with Icm^ 
of an emulsion containing 10 mg of ovalbumin (OVA) in Freund's 
complete adjuvant. After 11 days the rats were sacrificed. 
The lymph nodes were removed aseptically and minced in 
Dulbecco's A and B buffer containing 7% FCS (DAB/2% FCS) and 
dispersed by passage through a sterilised nylon screen. Large 
fragments were removed and discarded. Adherent cells were 
removed by passage through a Sephadex GIO column prewashed at 
37°. The cell suspension was washed three times in DAB/2% 
FCS.
Spleens were removed from non-immunised PVG rats and the 
cells separated in a similar manner. Extraneous red cells
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lysed with ammonium chloride buffer for 5 mins. and the cells 
were washed five times in DAB/2% FCS.
2.8 RAT CELL CULTURE
10^ lymphnode cells and 10^ spleen cells (macrophages) 
were cultured alone or in combination. The cells were cultured 
in RPMI 1640 containing 5% FCS and 10 pg cm“  ̂OVA in 0.2 cm^ 
flat-bottomed microtitre plates for 72 hours. 4 hours before 
termination of the incubation the cells were pulsed with
0.5|ici, tritiated thymidine (specific activity 5 ci mmol” )̂. 






3.1 SULPHYDRYL-DEPENDENT MONOCYTE-LYMPHOCYTE INTERACTIONS IN 
RHEUMATOID ARTHRITIS
3.1.1 The role of SH groups in the pathogenesis of Rheumatoid 
Arthritis
The role of SH groups in the pathogenesis of RA is poorly 
understood. This study was aimed at bringing together the 
experimental evidence of SH involvement in the immune 
response, the low serum SH levels in RA patients and the 
s u l p h y d r y l - r e a c t i v i t y  of antirheumatic drugs. The 
investigation assessed the role of SH groups in regulating 
monocyte-lymphocyte interactions in RA and the modulation of 
these parameters during treatment with D-pen.
3.1.2 The role of SH groups in the immune response
Serum SH levels are essentially determined by the number 
of albumin molecules which possess a free thiol. The thiol 
dependent serum factor (MaSF) described by Opitz et al. (1980) 
is biochemically very similar or identical to albumin. This 
may provide a link between the low serum SH level and 
immunological abnormalities characteristic of RA. If free SH
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groups on albumin are necessary for a normal immune response 
in vivo, it may be prevented by depressed serum thiols. Serum 
albumin has been shown to be absolutely necessary for human 
lymphocyte proliferation in response to PHA (Polet and 
Spieker-Polet, 1975; Spieker-Polet and Polet, 1976; Aral et 
al., 1977). This provides a useful assay system for 
determining the effect of reducing the available number of 
free albumin thiols on the immune response. This may be 
achieved in two ways, the albumin concentration in the assay 
may be reduced or the serum SH may be blocked biochemically.
3.1.3 The effect of reducing the available free thiols on 
mitogen stimulated PBMC proliferation in vitro
Experiments were carried out to determine whether the SH 
group on the albumin molecule is necessary for lymphocyte 
activation. The optimum concentration of PHA, l|ag cm~^, was 
determined in preliminary experiments. The use of albumin in 
the culture system made it possible to reduce the SH level 
simply by reducing the albumin. The results of this 
experiment are shown in Fig. 4. Maximum proliferation was 
obtained with the addition of 4mg cm”  ̂ BSA. This is a similar 
amount to that provided by the addition of 10% FCS. However, 
there was no significant difference between the responses with 
4 and 1 pg cm”  ̂ BSA. A four-fold reduction in albumin 
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assays human serum albumin (HSA) was added to the culture in 
place of BSA (Fig. 5). Again maximum proliferation was 
obtained with 1 - 4  mg. cm ” .̂ These data suggest that serum 
albumin thiols are not rate limiting for the in vitro immune 
response.
Experiments were carried out to determine whether or not 
a thiol dependent serum factor other than albumin is involved 
in the human immune response. Whole human serum was separated 
into fractions by passage through a Sepharose 6B column. The 
fractionation was monitored using a spectrophotometer. Five 
separate peaks were observed and these are shown in Fig. 6. 
The fractions representing each peak were pooled and 
concentrated to their original volume using an Amicon filter. 
The ability of each of the fractions to promote PBMC 
proliferation in the PHA assay was determined. The results of 
this experiment are shown in Fig. 7. The only fraction to 
promote PBMC proliferation was fraction 4. This is the 
fraction which contains albumin molecule - molecular weight 
68, 000. This finding does not however rule out the 
possibility of the existence of a thiol dependent serum 
factor, which is similar, but not identical, to albumin. This 
was investigated by reducing the SH level of whole human 
serum.
Normal serum was incubated with an irreversible SH- 
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Fig. 5. Effect of HSA on PHA response in serum 
free media. The bars represent % stimulation 
(mean + l.s.d.) compared to cells cultured in the 
absence of HSA or FCS n = 4. M a x i m u m
proliferation was obtained in cultures containing 










Fig. 6 . Protein fractions separated from whole 
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Fig. 7. PtiA-stimulated PBMC proliferation in 
response to each of five human serum protein 
fractions. Proliferation occurs only in the 
presence of fraction 4.
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100 - 600 piM dm  ̂ (Fig. 8). The serum was then added to 
autologous PBMC in a culture system containing PHA.
The results of these experiments are shown in Fig. 9. 
This shows that blockade of serum SH groups has no significant 
effect on PHA lymphocyte proliferation in vitro in the serum 
SH range representative of either normal healthy individuals, 
(600 pM dm"3 to 400 pM dm ” )̂ or for patients suffering from 
severe RA, (250 pM d m ”  ̂ to 200 pM d m ”^). Any SH-dependent 
serum factor does not appear to be rate limiting.
3.1.4 The effect of cell surface SH blockade on PHA- 
stimulated PBMC proliferation in vitro
It has been demonstrated that the addition of SH blocking 
agents to cell cultures results in the inhibition of lectin- 
induced proliferation (Chaplin and Wedner, 1978). Experiments 
were carried out to determine whether this inhibition was due 
to cell surface blockade rather than an effect on serum.
The effect of the presence of a non-penetrating SH 
blocking agent PHMPSA on healthy PBMC cultures is shown in 
Fig. 10. PHMPSA inhibited lymphocyte proliferation in a dose- 
dependent manner. 50% inhibition was achieved by the addition 
of 10 pM PHMPSA and proliferation was completely abolished in 
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Fig. 8. The effect of incubating serum with lOA 
on free SH levels. Incubation with a range of 
500 - 10,000 pM lOA produces serum SH levels of 
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Fig. 9. Effect of serum blockade on PHA response 
(n = 10). The bars represent % response of 
lymphocytes cultured with untreated serum (+
l.s.d.). Serum levels in the range 600 - 100 pM 
did not significantly affect PHA stimulated 
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Fig. 10. Effect of the addition of PHMPSA on PHA 
stimulated lymphocytes (n = 7). Bars represent % 
response to PHA compared to cells not treated 
with PHMPSA (+ 1 s.d.) The ID50 of PHMPSA was 
found to be 10 pM.
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The use of a non-penetrating SH blocking agent ensures 
that the inhibition is not due to intra-cellular SH blockade 
but it does not rule out the possibility that the effect is 
due to SH blockade of another component of the culture medium. 
To determine whether the inhibition was due to blocking cell 
surface SH group the PBMC were pre-incubated with PHMPSA and 
then washed prior to culture.
Pre-incubation of the PBMC resulted in similar dose- 
dependent inhibition of cell proliferation (Fig. 11). The 
effect of PHMPSA, was therefore, exerted on cell surface SH 
groups, and not on a component of the culture medium. 
Treatment of PBMC with PHMPSA did not affect cell viability as 
assessed by trypan blue exclusion after the 7-day culture 
period at 37C.
3.1.5 The role of thiols in monocyte accessory cell functions 
in the immune response in vitro.
The above data indicate that free SH groups on the PBMC 
surface are necessary for proliferation. The reason for their 
necessity was then investigated. Other investigators have 
shown that in animal culture systems thiols are involved in 
the accessory role of macrophages. Experiments were carried 
out to determine if this was so in the human immune response. 
The PBMC were separated into lymphocytes and monocytes by 














[P H M P S A ]
Fig. 11. Effect of preincubation of PBMC with 
PHMPSA on PHA stimulated cell proliferation (n = 
5). Bars represent % response to PHA compared to 
cells not preincubated with PHMPSA (+ 1 s.d.). 
The ID50 is again 10 pM.
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lymphocytes were then recombined. In the cell proliferation 
assay it proved impossible to consistently remove sufficient 
monocytes to abolish proliferation in response to PHA. 
Similar experiments were carried out using a PWM stimulated 
IgG synthesis assay system to determine whether this would 
provide a more consistent assay for the study of monocyte 
lymphocyte interactions.
Initial experiments showed that a final dilution of 
1/1000 PWM was optimal in this assay - although approximately 
10% of those subjects studied did not respond to PWM 
(Fig. 12). IgG production was measured using an ELISA 
technique. The optical density was measured and the level of 
IgG was calculated by reference to a calibration curve - an 
example of which is ilustrated in Fig. 13.
Pre-incubation of PBMC with PHMPSA also resulted in 
inhibition of PWM-stimulated IgG synthesis (Fig. 14). PBMC 
from healthy controls produced 2,234 + 173 ng IgG 10”^ cells 
in the presence of PWM. Only small amounts of IgG were
generated in the absence of PWM (59 + 20 ng 10“^ cells). Pre­
incubation of the cells for 60 mins. with 10 pM PHMPSA 
resulted in IgG synthesis being reduced to 1023 + 172 ng IgG 
10"G PBMC (approximately 50% inhibition). Again, 50 pM PHMPSA
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Fig. 12. Optimum PWM dilution required for IgG 
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Fig. 13. IgG calibration curve. The level of 
IgG production by PWM stimulated cultures was 
determined by reference to a calibration curve 
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Fig. 14. Effect of preincubation with PHMPSA IgG 
production (n = 3). Each histogram represents 
the mean IgG production in ng x 10  ̂ 10“  ̂ cells 
(+ I.s.d.).
10 pM.
ID 50 n. of PHMPSA was found to be
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The synthesis of IgG in response to PWM was more easily 
inhibited by monocyte depletion on 52% Percoll but this was 
not always achieved. The addition of an adherence step by 
which any residual monocytes in the lymphocyte fraction were 
removed by passage through a Sephedex GIO column proved very 
consistent and provided a reliable assay for the study of 
monocyte-lymphocyte interactions.
Evidence supporting monocyte dependence of IgG production 
by PWM stimulated PBMC and the involvement of cell surface SH 
groups in this accessory cell function is presented in 
Fig. 15. It is clear that purified lymphocytes cannot respond 
to PWM in the absence of monocytes. Recombination of 
lymphocytes and monocytes (ratio 5:1) gave a full recovery of 
IgG synthesis. However, if either the monocytes or the 
lymphocytes were pre-incubated with PHMPSA, IgG synthesis was 
abolished. Treatment of the monocytes or lymphocytes with 
PHMPSA showed a dose dependent inhibition similar to that seen 
by PWM stimulated IgG synthesis by PBMC and PHA stimulated 
lymphocyte proliferation (Fig. 16).
Cell surface SH groups are, therefore, necessary for some 
form of interaction between lymphocytes and monocytes and 
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Fig. 15. IgG production by healthy control 
mononuclear cell fractions stimulated with PWM 
(n = 6). Each histogram represents the mean IgG 
production ( ng x 10^ 10”  ̂cells) (+ l.s.d.) Cell 
fractions tested were: PBMC = peripheral blood 
mononuclear cells; Ly = purified lymphocytes; M (6 
= enriched monocytes; Ly + Mç6 = reconstituted 
mixture of lymphocytes and monocytes, ratio 5:1; 
Ly + M{ẑ  - PHMPSA) = reconstituted mixture of 
untreated lymphocytes and monocytes (pre-treated 
with the surface SH blocking agent PHMPSA) ratio 
5:1, Ly-PHMPSA + Mĝ  = reconstituted mixture of 
monocytes and lymphocytes pretreated with PHMPSA.
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Fig. 16. Effect of p r e i n c u b a t i n g  either 
lymphocytes or monocytes separately with PHMPSA 
(n = 5). The histograms on the left hand side 
each represent IgG production (ng x 10^ 10”  ̂
cells) by lymphocyte and PHMPSA preincubated 
monocytes (Ratio 5:1). The histograms on the 
right represent IgG production (ng. x 10  ̂ 10” ^ 
cells) by lymphocytes pretreated with PHMPSA and 
untreated m o n o c y t e s  (Ratio 5:1), (+ 1 s.d.)
Inhibition of IgG synthesis is dose dependent 
whether the lymphocytes or the monocytes are 
treated.
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This may explain the abnormal immune response 
characteristic of RA. If blocked SH groups extend from the 
serum to the PBMC surface it may result in an aberration of 
the immune system.
3.1.6 Experiment to determine if cell surface SH groups 
correlate with serum SH levels
Experiments were therefore carried out to determine if 
the cell surface SH groups correlated with serum levels. Cell 
surface SH may be measured by incubating the cells with 6,6'- 
D. This compound reacts with the cell surface thiols. After 
excess 6,6'-D has been removed part of the 6,6'-D molecule 
attached to the cell surface can be cleaved off. This 
compound, a thione, can be measured spectrophotometrically at 
344 nm. and is proportional to the number of free cell 
surface SH groups (Mehrishi and Grassetti, 1969). In order to 
demonstrate that this assay was a true indication of the 
number of free surface thiols PBMC were obtained from healthy 
volunteers and the cell surface thiols blocked with PHMPSA 
prior to assay. The PBMC were then incubated with 6,6'-D. 
The results presented in Fig. 17 show that the amount of 
thione released parallels the thiol blockade by PHMPSA.
Serum and PBMC were obtained from healthy volunteers and 
rheumatoid patients in order to provide a range of serum SH 









Fig. 17. Measurement of cell surface thiols 
after pre-incubation with PHMPSA. Cell surface 
thiols are reduced in a dose dependent manner 
after preincubation with PHMPSA.
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measured. The results are shown in Fig. 18. Serum and cell 
surface SH groups do have an association but do not correlate 
(r = 0.615, p > 0.05).
3.1.7 The effect of thiol compounds on IgG synthesis by PBMC 
from rheumatoid patients
If cell surface thiols on PBMC are blocked in rheumatoid 
patients resulting in immunological abnormalities, the 
addition of a reducing agent may restore the normal immune 
response. This was studied in vitro using the IgG assay. The 
effect of 2-ME on PWM stimulated IgG synthesis by 
unfractionated PBMC was determined. Initial experiments 
showed that the optimal level of 2-ME was 5 x 10~^M (Fig. 19). 
PBMC from healthy volunteers produced 2345 + 554 ng IgG 10”  ̂
cells in the presence of PWM PBMC from patients with active RA 
(RA-NSAID) synthesised significantly less IgG than normal 
cells in this assay (1623 + 450 ng 10”  ̂ cells, P < 0.005), 
whereas IgG production by PBMCs from D-pen treated patients 
(RA-D-pen) did not differ significantly from that of normal 
cells (P > 0.05) (Fig. 20). Fig. 20 also shows that the 
depressed level of IgG synthesis by RA-NSAID cells was 
enhanced to normal values by the addition of 2-ME (5 x 10"*̂  M) 
to the culture medium. This procedure did not significantly 







Fig. 18. Correlation of serum SH levels and cell 
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Fig. 19. Optimum level of 2-ME required to 
enhance IgG synthesis. The optimum level of 2-ME 










Fig. 20. Results are expressed as the mean IgG 
production (+ l.s.d.) by 10^ PBMC o p t i m a l l y  
s t i m u l a t e d  with PWM. IgG production in 
unstimulated cultures was the same (66 + 37ng 
10“  ̂ PBMC) in all three groups. In the absence 
of 2-ME, PWM stimulated RA-NSAID cells generated 
less IgG than healthy cells (P < 0.005). IgG 
production by RA-D-pen cells did not differ 
significantly from that of healthy control cells 
(P > 0.05). The addition of 2-ME (5 x 10“ ^M) to 
these cultures s i gnificantly increased IgG 
production by the RA-NSAID cells (P < 0.005) but 
not by healthy or RA-D-pen cells.
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These data suggest that blocked SH groups on the PBMC 
surface do result in depressed IgG synthesis by rheumatoid 
cells. Reduction with 2-ME resulted in normal IgG production. 
Patients treated with D-pen also showed a normal response 
which may suggest that this drug has a similar effect on PBMC 
to that of 2-ME.
3.1.8 The role of SH group monocyte-Iymphocyte interaction in 
rheumatoid patients
The sulphydryl blocking data showed that blockade of 
either lymphocytes or monocytes resulted in inhibiting the 
immune response in vitro.
Experiments were carried out to determine whether both 
the rheumatoid monocytes and lymphocytes have to be treated 
with 2-ME to obtain enhanced IgG synthesis. Lymphocytes and 
monocytes were separated and half of each cell type pre­
incubated with 2-ME. The cells were recombined in culture. 
The results presented in Fig. 21 show that both monocytes and 
lymphocytes from RA-NSAID patients have to be pretreated with 
2-ME to achieve enhanced IgG synthesis. This together with 
the other data suggest that free cell surface thiols are 
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Fig. 21. The effect of p r e - i n c u b a t i o n  of 
monocytes and lymphocytes from RA-NSAID patients. 
Both monocytes and lymphocytes have to be pre­
treated with 2-ME to achieve enhanced IgG 
synthesis.
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3.1.9 Experiments to determine whether blocked surface thiols 
affect monocyte accessory function in rheumatoid patients
These data suggest that the inhibition was due to an 
interaction between the lymphocytes and monocytes which may be 
relevant in RA.
The total dependence of PWM stimulated IgG production on 
the presence of monocytes permits a comparison of accessory 
cell function between individuals or patient groups, based on 
the titration curve of these cells added back to lymphocyte 
cultures. Fig. 22 illustrates the calculation of the monocyte 
EDgQ, i.e. the number of monocytes that are needed to 
reconstitute 50% of the m a x i m u m  IgG production by 10^ 
lymphocytes. The mean titration curve for three groups, 
healthy controls, RA-NSAID and RA D-pen are shown in Figs. 23,
24 and 25 respectively. The addition of 2-ME to the pure
lymphocyte culture system did not promote IgG production. 
Fig. 26 shows that medium monocyte ED50 for healthy cells was 
found to be 400 10"^ lymphocytes. Accessory cell function did 
not change significantly in the presence of 2-ME, an expected
finding in line with the data in Fig. 20. Monocytes from RA-
NSAID patients showed impaired accessory function, with a 
median EDgg value of 8000 10“  ̂ lymphocytes. This differs 
significantly from both healthy cells (P < 0.01, Mann-Whitney 
U test) and RA D-pen monocytes (P < 0.05, Mann-Whitney U 









M 0 added 10” ®Ly
Fig. 22. T i t r a t i o n  c urve to i l l u s t r a t e  
calculation of monocyte ED^Q. Standard deviation 
bars have been omitted for clarity. The dotted 
line illustrates the method of estimating the 
monocyte EDgg value, the number of monocytes 10"^ 
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Fig. 23. Titration curve for healthy control 
monocyte accessory function in PWM stimulated IgG 
production. The histograms on the left show that 
2-ME has no effect in the absence of monocytes. 
The histograms on the right show IgG synthesis 
(ng X 10^ 10^ cells), by unfractionated PBMC 
cells. The graph gives the mean response for 12 
experiments. Standard deviation bars have been 
omitted for clarity. The median monocyte ED^q is 
400 10“  ̂ lymphocytes.
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Fig. 24. Titration curve for RA-NSAID monocyte 
accessory cell function in PWM stimulated IgG 
production. The graph gives the mean response 
for 13 patients. The median monocyte ED^Q is 
8000 10”  ̂ lymphocytes. The histograms on the 
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Fig. 25. Titration curve for RA-D-pen monocyte 
accessory cell function in PWM stimulated IgG 
production. The graph gives the mean response 
for 14 patients. The median monocyte is
2000 10”  ̂ lymphocytes. The histograms on the 



















Fig. 26. Monocyte accessory function in PWM
stimulated IgG production for the three patient 
groups. Cells were cultured without (-) or with 
(+) 2-ME (5 X lO'^M). Accessory function is 
presented as monocyte FD50 values estimated as 
illustrated in Fig. 22. In the absence of 2-ME, 
the RA-NSAID group differs significantly from the 
healthy controls (P < 0.01, Mann-Whitney U-test) 
and from RA-D-pen patients (P < 0.05). Data from 
the control and RA-D-pen groups are not 
significantly different. The addition of 2-ME 
enhances monocyte accessory function only in the 
RA-NSAID group (P < 0.05).
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10“  ̂ lymphocytes), was not significantly different from 
healthy controls. In the presence of 2-ME the accessory 
function of RA-NSAID monocytes was significantly enhanced (P < 
0.05) but that of RA D-pen cells was not affected.
3.1.10 Serial study to determine the effect of D-pen therapy 
on monocyte accessory function in rheumatoid patients
Because the above patient groups were chosen specifically 
because they either had active RA or were established on D-pen 
with quiescent disease, a serial study was performed to 
determine whether the effects on monocyte accessory function 
were due to drug treatment or to disease activity. Initially 
15 patients with active RA starting a course of D-pen therapy 
were studied. Due to early drop-out or inability of their 
cells to be stimulated by PWM, complete data over a 6 month 
period were obtained on only 8 patients. Three case reports 
are presented here and are representative of the patients 
studied. Unfortunately only one patient responded well to D- 
pen therapy (Case 1) and it must be noted that this patient 
was not suffering from severe disease. The clinical and 
laboratory assessment of these three patients are presented in 
Tables 1, 2 and 3. The clinical assessments were undertaken 
by Dr. A. Woolf, Senior Registrar at the Royal National 
Hospital for Rheumatic Diseases, Bath.
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CASE 1
This was a 61 year old man who had a 4 year history of 
sero-positive RA. Extra-articular features were not present. 
He had not previously received any disease modifying therapy. 
This patient responded well to D-pen within 2-3 months with 
little active synovitis after 6 months therapy.
CASE 2
This was a 43 year old man with a 22 year old history of 
sero-positive RA, with no extra-articular features of the 
disease. This patient had received gold therapy in 1972 which 
resulted in a severe skin reaction. His symptoms improved 
after 3 months D-pen therapy with few symptoms after 6 months 
but active synovitis was still present on examination.
CASE 3
This was a 68 year old woman with a 9 year old history of 
sero-positive RA. Nodules and vasculitis were not present but 
the patient did suffer from Sjogren's syndrome.
This woman commenced D-pen therapy as an inpatient during 
which period she improved. Over a 5 month period the patient 
reported a non-specific improvement but still had widespread 
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TABLE 2. Clinical and laboratory assessment of
patient who responded slowly to D-pen therapy
(Case 2).
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PERIOD OF I 
ASSESSMENT 0 
(MONTH) !
1 2 3 6
D-pen Dose [ ' j
(mg day'll i 0 j 125 j  250 375 0
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TABLE 3. Clinical and laboratory assessment of
patient who did not repond to D-pen therapy (Case
3).
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and D-pen treatment was stopped due to thrombocytopenia.
Monocyte ED^q and IgG synthesis by these patients was 
monitored over the six month period. These parameters for the 
three case studies are presented in Fig. 27. The depressed 
IgG synthesis was steadily enhanced during the six months of 
D-pen therapy, irrespective of clinical improvement. The 
monocyte E D ^ q does however appear to reflect clinical 
improvement, a gradual reduction in Ed^g being achieved only 
in "Case 1". IgG synthesis and monocyte ED^q data were placed 
into two groups (responders plus slow responders) and (non­
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Fig. 27. IgG synthesis and monocyte ED^q levels 
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Fig. 28. IgG synthesis and monocyte ED50 levels 
















Fig. 29. IgG synthesis and monocyte ED50 levels 
of the clinical non-responders.
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3.1.11 Analysis of the action of 2-ME on monocyte-lymphocyte 
interactions
The stage at which 2-ME might exert its effect on 
monocyte-lymphocyte interaction was investigated. Mononuclear 
cell activation is mediated through complex interactions 
involving both cell:cell contact, necessary for antigen 
presentation, or through soluble mediators, for example the 
interleukins. Free SH groups may be necessary for any or all 
of these interactions.
3.1.12 Effect of 2-ME on interleukin production
Activated monocytes secrete lL-1 which acts on T-cells to 
stimulate the generation of lL-2 which in turn induces T-cell 
proliferation. As the lL-1 assay also detects lL-2 the lL-1 
supernatants were also screened for lL-2 activity in a PHA 
blast culture system. All these results proved negative (data 
not shown). Fig. 30 shows lL-1 production by monocytes from 
three groups, healthy controls, RA-NSAID and RA D-pen. 
Monocytes from RA-NSAID patients secrete significantly more 
lL-1 than healthy cells in response to LPS (P < 0.01, Mann- 
Whitney U test). These results contrast markedly with the 
previous findings of an overall impaired accessory function 
showed by rheumatoid cells. The addition of 2-ME to the 
monocyte cultures did not alter lL-1 production. This is 

















R A - D - p e n
Fig. 30. Effect of 2-ME on IL-1 production. The 
dots represent IL-1 production (LAF) in arbitrary 
units in the presence or absence of 2-ME by 
monocytes from 3 groups, normal healthy controls, 
RA-NSAID and RA-D-pen (n = 8). The lines connect 
the dots which represent IL-1 production by cells 
from the same patient. IL-1 produ c t i o n  is 
significantly greater by RA cells (RA-NSAID and 
RA-D-pen) than control cells (P < 0.01, Mann- 
Whitney U test). 2-ME had no effect on IL-1 
production.
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monocytes still showed elevated secretion of IL-1. The 
sulphydryl dependent step in the monocyte-l y m p h o c y t e  
interaction does not therefore appear to be IL-1 production. 
As it is IL-2 which actually induces T-cell proliferation the 
effects of SH groups on IL-2 production was also studied. IL- 
2 production was measured using cells isolated at the same 
time from the same blood samples as used for the lL-1 assays. 
There was no significant difference in lL-2 production between 
the three groups (P > 0.05, Mann-Whitney U test), although the 
values were very variable. The addition of 2-ME to the 
cultures did not have any significant effect (P > 0.05, Mann- 
Whitney U test) (Fig. 31). The production of interleukins 
does not appear to be sulphydryl dependent. The production of 
lL-1 and lL-2 did not correlate with each other (Fig. 32). 
Attempts to correlate levels of lL-1 and lL-2 production with 
clinical assessments of disease activity and also with 
biochemical parameters such as serum SH, CRP concentrations 
were unsuccessful and this data is presented in Table 4.
3.1.13 Studies involving antigen specific rat lymph node 
proliferation
Another possible stage at which 2-ME might exert its 
effect was antigen presentation. This would have proved 
difficult to study in a human system. Using facilities at the 
Lilly Research Centre antigen presentation was studied in a 









h e a l t h y
CONTROL
R A-NSAID R A - D - p e n
Fig. 31. Effect of 2-ME on IL-2 production. The 
dots represent IL-2 production in arbitrary units 
in the presence or absence of 2-ME from the same 
patients as Fig. 30, normal healthy controls, RA- 
NSAID, RA-D-pen (n = 8). The line connecting the 
dots which represent IL-2 production by cells 
from the same patient. There was no significant 
difference in IL-2 production from the 3 groups. 
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Fig. 32. C o r r e l a t i o n  of IL-1 and IL-2 
production. The graph shows no apparent 






(units 10”  ̂ cells)
IL-2 Production 
(units 10“  ̂ cells)
-SH CRP
-2ME + 2ME -2ME + 2ME



















IL-1 Production IL-2 Production -SH CRP
(units 10"° cells) (units 10 ° cells) ( |iN dir,"̂  ) ( ug orr^)
-2ME + 2.̂4£ -2.ME + 2ME
39 5 1  i 12.5 13 368 55
60.5 65 i 25 26.5 240 30
80 81.5 ' 13 19.5 365 46
69.5 70 1 81.5 90 197 38
95 97.5 j 28 34.5 1  295 57
54 57.5 24 28 375 18
72 77.5 55 58.5 262 < 10
86 90.5 10.5 15.5 222 19
RA-D-•PEN
Serum
IL-1 Production IL-2 Production -SH CRP
(units 10 cells) (unit s 10"^ cells) ( |uM dm.” ̂ ) ( pg csr,” )̂
-2ME + 2ME -2M£ + 2ME
57.5 66.5 28 26 426 31
52.5 55 15 18.5 308 22
33 37 89.5 100 332 < 10
64 62.5 19 17 406 40
73.5 71 62 67.5 477 114
76 76.5 70 90.5 275 15
91 92.5 47 53.5 418 37
81 89 38 58 263 27
Table 4. The relationship between IL-1, IL-2, 
serum SH level and CRP in the three patient 
groups.
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in an antigen specific lymph node proliferation assay. 
Initial experiments were set up to study a similar reaction to 
those already described for human PBMC. This assay system was 
chosen because of initial observations regarding the cell 
surface thiols on rat cells. Preincubation of rat lymph node 
cells with PHMPSA did not inhibit their proliferation in 
response to OVA. Experiments were carried out to determine 
whether this was due to cell surface thiols being already 
blocked. Preincubation of the cells with 2-ME prior to 
preincubation with PHMPSA did result in inhibiting 
proliferation. The degree of inhibition was too inconsistent 
to group the data from several experiments together, but an 
example is presented in Fig. 33. This suggested the surface 
SH groups on the rat lymph node cells oxidised very quickly.
Further experiments with the OVA stimulated rat lymph 
node proliferation assay showed that once the lymph node cells 
had been totally depleted of macrophages cell proliferation 
was dependent on both added macrophages and 2-ME (Fig. 34a). 
Lymph node cells in the presence of antigen and macrophages 
only produced a small amount of proliferation (150 + 75 CPM). 
The addition of 2-ME to the culture enhanced the cell 
proliferation to 16,003 + 6,552 CPM (Fig. 34b). The physical 
separation of macrophages and lymphocytes resulted in the 
absolute necessity for the presence of a reducing agent in the 
culture system. Pre-incubation of cells in 2-ME did not have 














cells  preincubated w ith  2ME prior 
to blockade
Fig. 33. The effect of PHMPSA on sensitised rat 
lymph node cells stimulated with OVA. Inhibition 

















LN - lymph node ce lls  
Sp= spleencells 
Ag = antigen(OVA)
LN Sp LN-Ag Sp-Ag LN-SpV\g
LN Sp LN-Ag 
2ME in Culture
Sp-Ag LN-SprAg
LN Sp LN-Ag S p A g  LN^SpV\c
ce lls  p re icuba ted  Wi th 2 ME
Fig. 34 a, b and c. The effect of 2-ME on 
cultures of adherent cell depleted rat lymph node 
cells. Adherent cell depleted lymph node cells 




LN 362 1  173 688 + 356
LN + Ag 96 1  43 500 + 126
LN + Sp 69 + 16 324 + 146
LN + Sp + Ag 427 + 132 16746 ±  292
Sp 53 ±  11 67 ±  11
Sp + Ag 30 + 13 43 + 15
PSp (+2ME) 35 + 27 65 + 15
PSp (+2ME) + LN 233 + 81 14487 + 589
PSp (-2M E ) 39 + 21 25 + 5
PSp (-2 M E )  + LN 91 + 36 13160 + 2156
Table 5. Rat lymph node proliferation
LN = Lymph node cells 
Ag = Antigen 
Sp = Spleen
PSp (+ 2-ML) = Spleen pulsed with antigen in the 
presence of 2-ME 
PSp ( - 2-I4E ) = Spleen pulsed in the absence of 
2-ME
Results are expressed as the mean cpm (n = 3). 
In the absence of 2ME in the cultures there is 
no proliferation above background. Lymph node 
cells in the presence of both spleen cells and 
2-ME showed enhanced proliferation (16746 + 
292), The presence of 2ME was not necessary for 
antigen presentation. There was no significant 
d i f f e r e n c e  (P > 0.05) in l y m p h  n o d e
proliferation in cultures containing spleen 
cells pulsed in the presence, PSp (+ 2ME) or 
absence, PSp (- 2ME) of 2ME.
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observations that the cell oxidised quickly and suggested that 
free SH groups were necessary for the monocyte and lymphocyte 
to physically interact.
Because this assay was a totally sulphydryl dependent 
monocyte-lymphocyte assay it was used to determine whether the 
thiol dependent step was antigen presentation. There was no 
significant difference (P > 0.05, Mann-Whitney U test), 
whether the macrophages were preincubated with antigen in the 
presence (14,487 + 589 CPM) or absence (13,160 + 2,156 CPM) of 
2-ME (Table 5).
Whilst free thiols did not appear to be needed for 
antigen presentation the data did show that rat cells are 





Monocytes play a central role in modulating lymphocyte 
functions. Hewlett (1977) proposed that the accessory role of 
the monocytes was mediated by an SH dependent immunoregulatory 
molecule (MaSF) which was similar or identical to serum 
albumin. Although the results presented here show that serum 
albumin is essential for an immune response in vitro, the 
possession of a free SH group was not necessary.
Hall et al., (1984) have suggested that the free SH group 
on the albumin molecule may scavenge oxidative species, 
especially hydrogen peroxide, generated during the 
inflammatory response, thereby preventing widespread tissue 
damage. The low levels of serum SH found in RA patients may 
therefore reflect a persistent inflammatory response that is 
generating large amounts of peroxides. Under these 
conditions, the protective effect of the albumin may be 
insufficient to prevent cellular damage.
In serum an equilibrium between albumin and small 
molecular thiols such as cysteine would be expected. This 
equilibrium would also extend to cell membrane thiols. It 
would seem reasonable to suppose that whatever oxidises the 
serum SH groups would also block the cell surface SH groups on
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the PBMC. An association between serum SH levels and the 
number of free SH groups on PBMC surfaces was found in this 
study. This finding supports the work of Lorber and Chang 
(1968) who found that the number of erythrocyte cell surface 
SH groups also correlated with the depression in serum SH 
levels. The results presented here show that cell surface 
thiols are necessary for a normal immune response. Chen and 
Hirsch (1972) suggested that these free SH groups are 
important at an early stage in PBMC activation. This is also 
supported by the findings of Chaplin and Wedner (1978), who 
found that the sulphydryl oxidising agent diamide was only 
effective when added within 30-60 minutes of the mitogen. 
These results suggest that the maintenance of free sulphydryl 
groups is important during the early induction of lymphocyte 
activation and indicates that an obligatory step or steps in 
the activation sequence may involve sulphydryl interactions.
The work of Rosenstreich and Mizel (1978) showed that the 
reducing agent 2-ME synergises with very small numbers of 
monocytes to restore their accessory role in IgG synthesis. 
This suggests that free SH groups on the monocyte cell surface 
are necessary for their accessory function. In agreement with 
other workers (Rosenberg and Lipsky, 1981), PWM stimulated IgG 
synthesis by human lymphocytes is totally dependent on added 
monocytes. However, the results presented here show that 
blockade of surface SH groups on either the monocytes or 
lymphocytes abolished their ability to synthesise IgG when
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recombined. This requirement for free cell surface SH groups 
for a normal immune response may explain the observed 
hyporesponsiveness of rheumatoid PBMC in vitro, since surface 
SH groups on these cells are partially blocked.
PBMC from patients with active RA were found to produce
less IgG than normal cells when stimulated with PWM in vitro 
and this confirms data reported by other investigators 
(Alarcon et al., 1982; Patel and Panayi, 1982; Poikonen et 
al., 1982; Plater-Zyberk et al., 1983). However, normal IgG 
synthesis was observed with PBMC from patients treated with D- 
pen, and the addition of 2-ME to the rheumatoid PBMC enhanced 
the depressed levels of IgG synthesis to those produced by 
both the healthy and D-pen treated cells. As the 2-ME had 
little influence on IgG production in the latter two groups it 
is possible that the enhancing effect of 2-ME in vitro had 
already been achieved by D-pen in vivo.
The monocyte titration experiments demonstrate that 
monocytes from patients with active RA show an impaired 
accessory function in the PWM stimulated culture sytem when
compared with normal cells. Similar results have been
obtained in a recent study on a small group of RA patients, 
(Plater-Zyberk et al., 1983). These authors did not have a 
completely monocyte-depleted assay, so quantitation of the 
differences between rheumatoid and healthy cells was not
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possible. The results presented here suggest that rheumatoid 
monocytes are as much as ten-fold less active as accessory 
cells than monocytes from normal controls. This contrasts 
with results from assays of monocyte phagocytosis in RA, which 
show normal cell function (Temple and Loewi, 1977; Bar-Eli, et 
al., 1980; Minty et al., 1983).
The accessory function of rheumatoid monocytes may be 
corrected in vitro by the addition of 2-ME (5 x 10”  ̂M) to the 
cultures. A similar improvement in monocyte accessory 
function seems to be achieved in patients following treatment 
with D-pen. Data from the monocyte titration curves suggest 
that the number of healthy monocytes that has to be added to 
obtain maximum IgG synthesis in vitro is 10^ 10”  ̂ lymphocytes 
(Fig. 23). This is less than the proportion normally found in 
PBMC. In contrast no such maximum appears to have been 
reached in the assay containing cells from rheumatoid patients 
treated with NSAID. Thus it is possible that had more than 
10  ̂ rheumatoid monocytes been added back to the system normal 
immunoglobulin synthesis might have been achieved.
These results therefore indicate that the impaired 
monocyte accessory function in patients with active RA is due 
to reversible blockade of surface SH groups, which will be re­
exposed following the addition of 2-ME or by D-pen treatment. 
The PBMC surface SH groups are probably depressed in active RA
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by oxidation and mixed disulphide formation with cysteine as 
are serum SH groups (Thomas and Evans, 1975) and probably also 
erythrocyte membrane thiols (Lorber and Chang, 1968). The 
depression of PBMC surface SH groups appears to affect certain 
cell functions, for example accessory function but not others, 
e.g. phagocytosis. It is suggested that cell surface SH 
oxidation may be responsible for some of the depressed PBMC 
functions displayed by rheumatoid cells in vitro.
The serial study of monocyte accessory function showed 
that enhanced IgG synthesis, in vitro, occurs rapidly 
following D-pen therapy regardless of clinical outcome. 
However, the monocyte ED^q was reduced steadily only in the 
one patient who showed marked clinical improvement. The 
monocyte titration assay may therefore provide a means of 
monitoring RA patients during D-pen therapy. Further research 
is being undertaken to determine whether this assay may have 
any predicative value. The need for such a test is emphasised 
by the fact that only one patient of the fifteen studied 
showed marked clinical improvement and this patient was not 
suffering from a severe form of the disease.
D-pen and 2-ME are both thiol compounds and it is 
proposed that their mode of action is similar in that they act 
as reducing agents, restoring the free SH groups that are 
necessary for a normal immune response and which have been 
oxidised in RA. This hypothesis may seem to contradict the
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explanation put forward by many workers that D-pen is an 
immunosuppressive drug (Maini and Roffe, 1976; Room and Maini, 
1981; Lipsky, 1981). This conclusion has been reached from 
experiments in which cells have been treated in vitro with D- 
pen. These workers report that 0.1 mg cm”  ̂ is required to 
inhibit lymphocyte proliferation and immunoglobulin secretion. 
Maini and Roffe (1976) have however shown that in whole blood 
cultures 1 mg cm“  ̂ was needed to inhibit PHA stimulated 
lymphocyte proliferation whereas 1 pg cm”  ̂ and 100 pg cm~^ D- 
pen augmented the response. Thus D-pen may have a biphasic 
effect similar to the effect of 2-ME on IgG synthesis 
presented here, augmenting the immune response in vitro at low 
concentrations and inhibiting it at high concentrations. The 
levels of D-pen measured in the serum of RA patients being 
treated with the drug are generally in the range 5 - 15 jig 
cm” ,̂ ten times less than that needed to inhibit PBMC
responses in vitro. It is also important to remember that 90%
of the D-pen is protein-bound. The work of Lipsky (1981) and
Lipsky and Ziff (1982) is interesting in that, contrary to 
Room and Maini (1981), they found that copper was necessary to 
obtain the inhibitory effect of D-pen. Lipsky and Ziff (1982) 
proposed that this immuno-suppressive effect was due to the 
copper-chelating properties of D-pen. They suggest that a 
complex is formed in culture between the D-pen and the copper 
ion and this D-pen-copper complex is the inhibitory moiety. 
Lipsky (1984) proposed that the effect of D-pen in the
presence of copper was inhibition of helper T-lymphocytes
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involving the generation of hydrogen peroxide. A likely 
explanation for these apparently contradictory results is that 
whilst Room and Maini added 100 |ig c m ”  ̂ of D-pen for the 
entire culture period, Lipsky (1978) and Lipsky and Ziff 
(1982) pre-incubated the cells with the drug in serum-free 
medium. A great deal more D-pen would be available than in 
the presence of serum, either in vitro or in vivo. The copper 
would act as a powerful catalyst for the oxidation of the cell 
surface SH groups on PBMC. The D-pen and copper might 
therefore act in the same way as PHMPSA. Lewins et al., 
(1982) also report a dose dependent suppression of IgG 
production but found that the presence of D-pen was needed at 
the initial stage of the culture. This would confirm the 
results presented here that the free SH groups are essential 
for normal immunoregulation, but it is not realistic to 
conclude that the action of D-pen is immunosuppressive, but 
rather that at the levels found in the sera of D-pen treated 
RA patients is probably in fact the opposite, immuno-  
stimulatory. The work of Room and Maini (1981) is also 
interesting in that they reported that cells from rheumatoid 
patients were less susceptible to inhibition by D-pen than 
normal cells. This may well be due to the SH groups already 
being partially blocked.
Monocytes from rheumatoid patients treated with NSAID 
only secreted significantly higher amounts of IL-1 than did 
monocytes from healthy controls. This contrasts markedly with
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the previous results of an overall depression in accessory 
cell function by rheumatoid monocytes. This enhanced IL-1 
production may indicate that monocytes from RA patients are in 
a state of activation. The resultant immune and inflammatory 
responses induced by IL-1 may well contribute to the 
immunopathogenesis of RA, however it does not seem to be the 
SH-dependent reaction within overall monocyte accessory 
function. The addition of 2-ME to the cultures in vitro did 
not affect the enhanced IL-1 secretion. D-pen therapy did not 
affect IL-1 production in vitro. SH groups do not therefore 
appear to be involved in IL-1 production. Rheumatoid T cells 
did not repond to the IL-1 enhanced level by generating 
excessive amounts of IL-2. Indeed, IL-2 production by 
rheumatoid cells was in fact modestly lower than normal, which 
is in agreement with a recent report from Alarcon-Segovia et 
al. (1984). Again the addition of 2-ME in vitro or D-pen 
treatment in vivo had no significant effect on IL-2 
production. IL-1 production did not, as might be expected, 
correlate with IL-2 production. This may support the 
possibility that IL-1 is not a single molecule and the IL-1- 
like activity present in the culture media may be different 
depending on the disease state of the donor's cells. The 
correlation of IL-1 with clinical assessment of disease 
activity and also with biochemical parameters such as serum SH 
and CRP failed to show any significant associations. The SH 
dependent step in the interaction between lymphocytes and 
monocytes does not therefore appear to involve the 
interleukins.
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The experiments with rat lymph node cells showed that 
removal of adherent cells by passage down a Sephadex G-10 
column abolished antigen stimulated lymphocyte proliferation. 
This is consistent with reports from others workers and with 
the work presented here. However, the response could only be 
recovered with added macrophages in the presence of 2-ME and 
not by pre-incubation of cells with 2-ME alone. The 
unresponsiveness of rat cells to PHMPSA blockade suggests that 
their SH groups oxidise very quickly, also a characteristic of 
rat serum SH groups (Butler et al., 1969). These results are 
interesting for two main reasons. First, they provided an 
assay system for determining whether free SH groups were 
necessary for antigen presentation. The results show that the 
presence of free SH groups on macrophages are not obligatory 
for antigen presentation. There was no significant difference 
in lymph node cell proliferation whether macrophages were 
pulsed with antigen in the presence or absence of 2-ME. 
Secondly, the results provided an insight into why cell 
surface SH groups are necessary for a normal immune response. 
The adherence of the macrophages to the Sephadex G-10 column, 
and the subsequent elution of the lymphocytes may result in 
the breaking of some physical interaction between the 
lymphocytes and macrophages involving the formation of 
disulphide bonds between SH groups on the two cell types. 
Because the SH groups auto-oxidise very quickly, the addition 
of 2-ME to the culture medium may be necessary to allow these 
bonds to be formed again for cell proliferation to take place.
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Results obtained using rheumatoid monocytes and lymphocytes 
are consistent with this idea, since both cell types had to be 
treated with 2-ME before enhanced IgG synthesis was observed. 
This suggests that oxidised cell surface SH groups prevent a 
normal interaction between the monocytes and lymphocytes.
Lymphocytes interact physically with monocytes during the 
in vitro immune response to antigens. This interaction is 
manifested by a characteristic formation of cell clusters, 
(Werdelin et al., 1974). These cell clusters consist of a 
monocyte surrounded by lymphocytes. Cluster formation is also 
observed in mitogen stimulated cultures (Hawkes and Kennedy, 
1984, personal communication). These workers report that IgG 
synthesis by PBMC stimulated with PWM was inhibited in a dose 
dependent manner by a mixture of D-pen and copper sulphate. 
This mixture also inhibited cell clustering stimulated by both 
PHA and PWM. Whether these observations have any relevance to 
the in vivo mode of action of D-pen or whether the drug is 
merely acting as a blocking agent at unrealistic levels is 
unclear. These findings are however consistent with the 
results presented here in that both suggest SH groups are 
involved in the physical interaction between lymphocytes and 
m o n o c y t e s .  W h i l s t  this h y p o t h e s i s  e x p l a i n s  the 
hyporesponsiveness found in in vitro stimulated PBMC, the 
situation in vivo is in fact the reverse. The nature of the 
disease is often one of hyper-activity of the inflammatory and 
immune responses. The answer may lie in the fact that
- 115 -
in vitro cultures employ PBMC. The situation in the synovium 
may be quite different. The macrophage lymphocyte 
interactions initiated by an unknown antigen may be locked 
together by the oxidative conditions in the synovium. This in 
turn would cause the production of oxidative species resulting 
in a positive feedback loop which may account for the 
u n c o n t r o l l e d  i n f l a m m a t i o n  and t i s s u e  d e s t r u c t i o n  
characteristic of RA. The free SH groups provided by D-pen 
treatment may simply act as a reducing agent to alter the 
oxidative conditions and end the positive feedback (Fig. 35). 
The delayed action of the drug may reflect a necessary build 
up of drug levels in tissue to achieve an effect. However, 
such is the uncertain nature of the mechanism by which 
lymphocytes and macrophages interact and the factors which 
regulate their responsiveness that any non-specific modulation 
of them must be somewhat unstable and unpredictable. There is 
the constant possibility that its beneficial effects may be 
reversed resulting in further defects in the immune system. 
Amongst the relatively high incidence of adverse reactions to 
D-pen are the production of auto-antibodies, auto-immune 
phenomena and auto-immune diseases other than RA. Jaffe 
(1979) has reported D-pen induction of pemphigus, myasthenia 
gravis, Sjogren's syndrome, Goodpasture's syndrome, systemic 
lupus erythematosus, polymyositis, immune complex nephropathy, 
thyroiditis, and haemolytic anaemia. Similar side effects 
have also been reported with other thiol drugs (Jaffe, 1980).
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If the thiol containing drugs such as D-pen are the first 
of a new generation of antirheumatic drugs the future may lie 
in compounds which modulate SH dependent immune reactions in a 
more specific way, producing beneficial effects in more 
patients with fewer adverse reactions.
synovium
c e lls  locked together
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